Davita Inc vs Kaltura Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Davita Inc is far larger — about 56.7× Kaltura Inc's market cap, and Davita Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Kaltura Inc for 21 Days on average.
| DVA | KLTR | |
|---|---|---|
Market Cap | $11.29B | $199.08M |
Volume | 582,204 | 175,927 |
Sector | Health | Technology |
52-Week High | $240.96 | $1.89 |
52-Week Low | $103.87 | $1.08 |
Typical Hold Time | 114 Days | 21 Days |
Enterprise Value | $24.01B | $211.29M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
KLTR trades at $1.32, down 0.75% on the day, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though it remains unprofitable with negative ROE. Recent analyst coverage leans positive with 44% buy ratings, supported by multiple industry awards and AI platform deployments in 2026.
The outlook remains speculative given persistent losses and high valuation ratios, but growing AI integration and award recognition provide catalysts. Key risks include cash burn, competitive pressure, and execution challenges in achieving profitability. Wall Street sentiment is cautiously optimistic despite technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →